Evaluating the best time to intervene acute liver failure in rat models induced by d-galactosamine by Eboli, Ligia Patricia de Carvalho Batista et al.
Acta Cirúrgica Brasileira - Vol. 31 (12) 2016 - 783
2 – ORIGINAL ARTICLE 
MODELS, BIOLOGICAL
Evaluating the best time to intervene acute liver failure in rat models induced by 
d-galactosamine1
Lígia Patrícia de Carvalho Batista ÉboliI, Alcides Augusto Salzedas NettoII, Ramiro Antero de AzevedoIII, Valéria Pereira 
LanzoniIV, Tatiana Sugayama de PaulaV, Alberto GoldenbergVI, Adriano Miziara GonzalezVII
DOI: http://dx.doi.org/10.1590/S0102-865020160120000002
IFellow Master degree, Postgraduate Program in Interdisciplinary Surgical Science, Universidade Federal de São Paulo (UNIFESP), Brazil. Technical 
procedures, design of the study, manuscript preparation. 
IIPhD, Assistant Professor, Department of Surgery, UNIFESP, Sao Paulo-SP, Brazil. Scientific and intellectual content of the study, acquisition of data, 
technical procedures, critical revision.
IIIPhD, Assistant Professor, Pediatric Department, UNIFESP, Sao Paulo-SP, Brazil. Scientific, intellectual, conception and design of the study; 
acquisition, analysis and interpretation of data.
IVPhD, Assistant Professor, Department of Pathology, UNIFESP, Sao Paulo-SP, Brazil. Analysis and interpretation of data, histopathological 
examinations, critical revision.
VGraduate student, School of Medicine, UNIFESP, Sao Paulo-SP, Brazil. Acquisition of data, technical procedures.
VIPhD, Associate Professor, Department of Surgery, UNIFESP, Sao Paulo-SP, Brazil. Scientific and intellectual content of the study, acquisition of data, 
critical revision.
VIIPhD, Associate Professor, Department of Surgery, UNIFESP, Sao Paulo-SP, Brazil. Scientific, intellectual, conception and design of the study; 
acquisition, analysis and interpretation of data; technical procedures; critical revision.
ABSTRACT
PURPOSE: To describe an animal model for acute liver failure by intraperitoneal d-galactosamine injections in rats and to define when 
is the best time to intervene through King’s College and Clichy´s criteria evaluation. 
METHODS: Sixty-one Wistar female rats were distributed into three groups: group 1 (11 rats received 1.4 g/kg of d-galactosamine 
intraperitoneally and were observed until they died); group 2 (44 rats received a dose of 1.4 g/kg of d-galactosamine and blood and 
histological samples were collected for analysis at 12 , 24, 48 , 72  and 120 hours after the injection); and the control group as well (6 
rats). 
RESULTS: Twelve hours after applying d-galactosamine, AST/ALT, bilirubin, factor V, PT and INR were already altered. The peak was 
reached at 48 hours. INR > 6.5 was found 12 hours after the injection and factor V < 30% after 24 hours. All the laboratory variables 
presented statistical differences, except urea (p = 0.758). There were statistical differences among all the histological variables analyzed. 
CONCLUSION: King’s College and Clichy´s criteria were fulfilled 12 hours after the d-galactosamine injection and this time may 
represent the best time to intervene in this acute liver failure animal model.
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Introduction  
Acute liver failure (ALF) is a rare and severe 
manifestation resulting from sudden and intense hepatocellular 
necrosis, associated with jaundice, coagulopathy and a certain 
degree of liver encephalopathy within the first 8 weeks of the 
appearance of the symptom and the absence of any previous liver 
condition1,2. 
This is associated with a high mortality rate of 40-
50%, depending on the cause and the therapeutic management3. 
The etiologies are much varied and the most common are drug 
intoxication and viral hepatitis4.
Liver presenting acute failure may recover and 
regenerate, however in most cases the deterioration might be 
quick for a possible recovery. Currently, in the USA, 45% of the 
adults have spontaneous recovery and 25% require liver transplant 
as the only life saving therapy5. Early identification in patients 
who will not survive with support therapy alone is fundamental 
for indicating liver transplantation. The prognostic evaluation 
criterion mostly used for this is King’s College6. Meta-analysis 
studies have confirmed its specificity (80%), but reported limited 
sensitivity (70%)7. To overcome this limitation, other prognostic 
criteria might be used, such as Clichy´s criteria, which takes into 
consideration the alterations of factor V coagulation, the patient’s 
age and the presence of encephalopathy8.
Hepatocytes transplant has been proposed for ALF 
treatment. In this technique, the human hepatocytes are infused in 
the splenic vascular, the portal or the peritoneal cavity to provide 
liver function to the sick liver. Although there are reports of 
successful errors of congenital metabolism the challenges used in 
acute liver failure are considerable9.
Therefore it becomes highly desirable to have an 
adequate experimental model for available acute liver failure 
in order to provide a better understanding of this condition and 
enables to develop new therapeutic approaches with the aim of 
extending the survival until the liver transplant takes place or the 
sick liver regenerates.
In the worldwide literature, the model for inducing 
acute liver failure via toxins in rats has been mostly used to test 
support therapies consist of d-galactosamine intraperitoneal 
administration, because it is potentially reversible, presenting 
non-significant extra-hepatic toxicity and has the best-defined 
hepatotoxic dosage10.
However, the descriptions of this model are very 
superficial, thus the reproducibility in other research centers are 
becoming more difficult. Moreover, studies using d-galactosamine 
induced ALF model to test therapies have been empirical and 
interventions were separated without following clinical parameters. 
The experiment report was conducted with the aim 
provide a more detailed description of d-galactosamine induced 
ALF that would enable to apply  King’s College and Clichy´s 
criteria, in order to establish clinical time to intervene.  
Methods
This project was approved by the Research Ethics 
Committee at UNIFESP (0197/12) and all the experiments using 
laboratory animals followed the norms.  
Experiments were performed at Laboratory of Surgical 
Technique and Experimental Surgery, Department of Surgery, 
Universidade Federal de São Paulo (UNIFESP). The rats were 
acquired at the Development Center for Medical and Biological 
Experimental Models (CEDEME), UNIFESP. 
Sixty-one Wistar female rats weighing between 195 g and 
251 g were used. The rats were maintained in an animal facility 
inside plastic cages measuring 40 x 34 x 17 cm with a maximum 
of five rats in each cage under a controlled temperature of about 
22ºC with artificial illumination, a sleep-wake cycle control, water 
and available food ad libitum. 
The animals were distributed into the following groups:
Group 1 – Composed of eleven rats were being 
observed regarding mortality for a period of time, after applied an 
intraperitoneal d-galactosamine injection of 1.4 g/kg. Craniotomy, 
thoracotomy and laparotomy were performed after their death, 
so that the brain, heart, lung, kidneys, spleen, pancreas and liver 
could be removed for histological analysis. 
Group 2 - Composed of 44 rats intraperitoneal 
d-galactosamine injection of 1.4 g/kg was applied.  After each 12, 
24, 48, 72 and 120 hours, six rats were chosen according to the 
severity criteria of the clinical manifestation presented by each 
rat. The rats were subjected to intraperitoneal anesthesia using 50 
mg/kg of ketamine (Dopalen, Vetbrands Brazil) and 20 mg/kg of 
xylazine (Virbaxyl 2%, Virbac, Brazil), followed by laparotomy 
and thoracotomy in order to collect blood by intracardiac puncture 
until exsanguination and death.   After the animals´ death, heart, 
lung, kidney, spleen, pancreas, and liver were removed for 
histological analysis. Soon after, craniotomy was performed to 
remove the brain.
Group 3 – The control group was composed by six 
rats and were observed for a period of seven days. Then they 
were anesthetized intraperitoneally by applying  50 mg/kg of 
ketamine (Dopalen, Vetbrands Brazil) and 20 mg/kg of xylazine 
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(Virbaxyl 2%, Virbac, Brazil) and  subjected to  laparotomy and 
thoracotomy in order to collect blood by intracardiac puncture until 
exsanguination and death. After the animals´ death, heart, lung, 
kidney, spleen, pancreas, and liver were removed for histological 
analysis. Soon after, craniotomy was performed to remove the 
brain.
D-galactosamine preparation 
Hydrochloride d-galactosamine (C6H13NO5-HCl) 
(Genese diagnostic product Inc.) is found in the form of white 
colored powder in bottles of 5g. To dilute, the drug was aliquoted 
under laminar flow, using a sterile spatula being removed from 
the bottle of origin and placed in a 50ml falcon tube. A semi-
analytical scale (Crystal 200 smi) with a precision of 0.001g, 
previously calibrated and tared with the weight of an empty falcon 
tube used for weighing the drug. The falcon tube was added 3.5g 
of D-galactosamine, 40ml of 0.9% saline solution and used a 
vortex shaker mixing the solution until it obtained a clear liquid, 
without residues. This concentrated solution, 8.75% (3.5g of 
D-galactosamine: 40ml of saline solution) were injected 16 ml/
Kg of weight in each rat intraperitoneally, equivalent to a dose 
of 1.4g/kg of D-galactosamine residues. Taking the risk of skin 
irritation and contact with dermatitis, each person used individual 
protection material (gloves, apron and glasses) to manipulate the 
drugs.
Intraperitoneal injection
To proceed to the intraperitoneal injection of the drugs, 
the rats were held with their belly up and with the head slightly 
inclined downwards in order to move the viscera and intestinal 
loops toward the diaphragm and to reduce the risk of puncturing. 
The rats were weighed and the dose to be administered was 
calculated with one decimal place and pipette was transferred from 
the falcon tube to a sterile test tube. The solution was removed by a 
5ml syringe coupled to a 22G needle (0.7 x 25mm) and applied in 
the lower left quadrant of the abdomen. The needle was introduced 
making an angle of approximately 45° and before injecting the 
drug, a mild aspiration was performed to be certain that it did not 
reach the bladder, the intestine or a blood vessel.
Common surgical procedure for all rats
To remove the organs, the rats were anesthetized with 
50mg/kg of Ketamine (Dopalen, Vetbrands, Brazil) and 20mg/kg 
of xylazine (2% Virbaxyl, Virbac, Brazil), applied intraperitoneally, 
except group 1 which had their organs removed after their death. 
The rats were placed in the dorsal decubitus position 
on the surgical board and had their limbs laid down. Antisepsis 
containing 70% alcohol was performed previously on the 
abdominal and thoracic walls and the rats were submitted to 
laparotomy and thoracotomy of the abdominal wall and thoracic 
anatomic planes section. 
With a 5 ml syringe coupled to a 22G needle (0.7x25mm), 
a heart puncture was performed to remove blood until the rat died. 
The blood was distributed in microsampling tubes (0.5ml for the 
purple tube EDTA; 0.6ml for the yellow dry tube and 1.8ml for 
the sodium citrate blue tube) for later analysis, and the rest was 
discharged. 
Liver, spleen, pancreas, right kidney, heart and right lung 
were removed from the abdominal and thoracic cavity. After the 
removal of the organs, the abdominal and thoracic walls were 
closed by stitching. 
Subsequently the rat was placed in ventral decubitus 
position on the surgical board with the limbs laid down and 
submitted an opening of the skin to expose the cranial followed 
by a craniotomy and a withdrawal of the brain. The organs were 
prepared on the surgical board and submitted to thin cuts with 
a cold bladed scalpel. The cut of each component was placed in 
a 10% formaldehyde solution in sterilized jars identified with a 
number for each rat.
Histological analysis
All the rats in this study were subjected to histological 
analysis of the liver, spleen, pancreas, kidney, heart, lung and 
brain.
The histological slides were analyzed by the same 
professional with an optical microscope, blindly, without knowing 
which slide belonged to which rat.
The semi-quantitatively hepatic histological variables 
were analyzed, as followed:
•	 Hepatocellular necrosis: 0- absent; 1- slight (foci of ne-
crosis, sometimes confluent); 2- moderate (extensive ar-
eas of confluent necrosis); 3- intense (extensive confluent 
necrosis as bridge or in panacinar form);
•	 Apoptosis: 0- absent; 1- slight; 2- moderate; 3- severe;
•	 Bleeding: 0- No; 1- Yes;
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•	 Steatosis was evaluated regarding the following types: 
predominantly macrovesicular; or predominantly mi-
crovesicular and mixed. 
Laboratory analysis
The rats in group 2 were sacrificed at 12, 24, 48, 72 and 
120 hours after the intraperitoneal d-galactosamine injection. 
Blood samples were collected by intracardiac puncture at a time 
after applying the anesthesia using ketamine and xylazine. The 
withdrawal of blood samples from the rats for analysis was also 
submitted from the control group 3. The following variables were 
analyzed: 
•	 Aspartate aminotransferase (AST) and alanine amino-
transferase (ALT);
•	 Bilirubin (total and fractions);
•	 Urea and creatinine;
•	 Factor V, prothrombin time (PT) and INR;
•	 Albumin.
Statistical analysis
To compare the numerical laboratory variables of the 
rats, the Kruskal-Wallis non-parametric test was used because of 
the small sample size (maximum of 6). Regarding to detect the 
differences between evaluation times, Dunn-Bonferroni´s multiple 
comparisons were used to identify such differences. 
The existence of the associations between the histological 
categorical variables was ascertained by using Fisher’s exact test 




Macroscopically the dead rats´ livers presented a pale 
coloring (Figure 1) when compared to a normal liver (Figure 2) 
and with some hemorrhagic focuses. Hemorrhagic focuses in the 
lung could also be observed, as well as food stasis in the stomach 
and intestinal loops.
FIGURE 1 – A rat´s liver that received D-gal.               
 
FIGURE 2 – A controlled rat´s liver.
Clinical findings and mortality
From observing the rats in group 1, that received doses 
of 1.4 g/kg of d-galactosamine, was noted that 27 hours after the 
injection, some rats began to present hemorrhagic suffusions on 
the tail and nose and, after 49 hours, they presented limb spasms 
and seizures. Other symptoms presented were restlessness, itching 
or hyporesponsiveness.
The first death occurred 44 hours after the d-galactosamine 
injection. The mortality peak occurred between 49 and 60 hours 
(n = 5). The last death was registered at 76 hours after taking 
d-galactosamine.
120 hours after applying the injection, three of the eleven 
rats were still alive (mortality rate of 73%). 
In group 2, after 48 hour there were only ten animals 
alive. So, it was possible to sacrifice only 4 animals at 72h and 
120h period.
Laboratory findings
Twelve hours after applying d-galactosamine injection, 
it was already possible to observe the alterations in the liver 
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enzymes (Table 1) and the decrease of the coagulation factors 
(Table 2). The peak for this alteration occurred 24 hours after 
taking d-galactosamine. 
All the laboratory variables studied, presented a 
statistically significant difference according to Kruskal-Wallis 
test, except urea (Tables 3 and 4). Using the Dunn-Bonferroni test 
to identify the differences, it could be seen that the values reached 
the variables and were similar at zero hour and at 120 hours after 
applying the injection, and these were different from the values 
presented at 24 and 48 hours after applying the injection.
King’s College criterion (INR > 6.5) were fulfilled at 
12 hours after taking the drug and Clichy´s criterion (Factor V < 
30%) was after 24 hours (Table 2).















AST 91.5A 4.810 16.015B 7.778B 1.120 77A <0.001
ALT 60A 3.581 16.002B 9.498B 1.083 43.8A <0.001
1Descriptive level of Kruskal-Wallis test
(A) and (B) are distinct according to Dunn-Bonferroni multiple comparisons















Factor V 260.5A 125 23,5B 40 288.5A 268A 0.001
INR 1.54A 7.52 10B 10B 1.84 1.46A <0.001
PT 18.4A 58.5 71B 71B 20.6A 17.3A <0.001
1Descriptive level of Kruskal-Wallis test
(A) and (B) are distinct according to Dunn-Bonferroni multiple comparisons















Albumin 4.4A 4.2 A,a 3.7B 3.3B,b 3.4 4.2 0.001
Urea 46.5 47.5 42.5 42 39 43 0.758
Creatinine 0.4 0.4 0.6A 0.2B 0.4 0.3 0.005
1Descriptive level of Kruskal-Wallis test
(A) and (B) are distinct according to Dunn-Bonferroni multiple comparisons
(a) and (b) are distinct according to Dunn-Bonferroni multiple comparisons















BT 0.05A 0.22 1.6B 3.99B 4.91B 0.09 <0.001
BD 0.04A 0.06 1.28 3.34B 4.17B 0.06 0.001
1Descriptive level of Kruskal-Wallis test
(A) and (B) are distinct according to Dunn-Bonferroni multiple comparisons
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Microscopic findings 
Histological sections through the rats´ livers in group 
1 showed extensive areas of confluent necrosis, sometimes 
compromising zones 1 and 2, accompanied by lymphomononuclear 
or lymphohistiocytic inflammatory infiltrate, sometimes with 
the presence of neutrophils. The remaining parenchyma showed 
ballooned hepatocytes, retraction figures and acidophilus 
corpuscles, along with slight macro and microvesicular steatosis. 
In some rats, slight ductular reaction in zone 1 was observed.
Histological analysis on liver sections over the course of 
time showed that 12 hours after taking the drug, foci of necrosis 
and apoptosis could be seen (Figure 3). These became more 
intense after 24 and 48 hours (Figures 4 and 5), but then practically 
normalized after 72 hours (Figure 6 and Table 5). Ballooning 
and ductular reaction appeared later on, thus suggesting that 
parenchymal regeneration was occurring (Figure 7).
 
FIGURE 3 - Histological section of a sacrificed rat´s  liver at 12 hours, 
featuring multiple apoptotic bodies (thin arrows) and foci of necrosis 
(wide arrows) accompanied by mixed inflammatory infiltrate. (HE x200)
FIGURE 4 - Histological section of a sacrificed mouse´s liver at 24 hours 
with a large quantity of apoptotic bodies (thin arrows) and foci of necrosis 
(wide arrows) located predominantly near hepatic terminal vein (VHT). 
(HE x150) 
FIGURE 5 - Histological section of a sacrificed rats´ livers at 48 hours 
presenting confluent areas of necrosis accompanied by inflammatory 
infiltrate lymphomononuclear cells (wide arrows), numerous apoptotic 
bodies (thin arrows), ballooned hepatocytes (★) and steatosis 
macrogoticular located predominantly in zone 3. (HE x150)
FIGURE 6 - Histological section of a sacrificed rats´ livers at 72 hours 
showing rare foci of necrosis accompanied by inflammatory infiltrate 
lymphomononuclear cells (arrows) and macro and microgoticular 
steatosis. (HE x100)
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TABLE 5 – Semi-quantitative analysis of the histopathological changes in the liver presented by the animals in the control 
group and group 2 for a period of time. 
Time (hour)
Control
Group* 12h  24h 48h 72h 120h P value
1
N % N % N % N % N % N %
HEMORRHAGE 5 100% 6 100% 6 100% 6 100% 4 100% 4 100% <0.001
No 5 100% 5 83.3% 0 0% 2 33.3% 4 100% 4 100%
Yes 0 0% 1 16.7% 6 100% 4 66.7% 0 0% 0 0%
STEATOSIS 5 100% 6 100% 6 100% 6 100% 4 100% 4 100% <0.001
Absent 5 100% 0 0% 0 0% 0 0% 1 25% 2 50%
Macrogoticular 0 0% 1 16.7% 0 0% 0 0% 1 25% 0 0%
Microgoticular 0 0% 5 83.3% 5 83.3% 1 16.7% 0 0% 0 0%
Mixed 0 0% 0 0% 1 16.7% 5 83.8% 2 50% 2 50%
*Material loss of one animal
1Descriptive level of Kruskal-Wallis test
 
FIGURE 7 - Histological section of a sacrificed rats´ livers at 120 
hours presenting discrete not specific reactive changes represented by 
hyperplasia and hypertrophy of Kupffer cells. (HE x200)
All histological variables analyzed by Fisher’s exact test 
presented statistically significant differences (Tables 5 and 6).
Portal and lobular infiltrates, along with steatosis, could 
be observed 12 hours after drug administration. 
The remaining analyzed organs (lung, heart, kidney, 
brain, spleen and pancreas) did not present any significant 
alterations, except for the kidneys of some rats that were sacrificed 
48 hours after the d-galactosamine injection. These presented 
isomeric intracytoplasmic microvacuolation in contorted tubules. 
One rat was also sacrificed 48 hours after the injection presented 
pancreatic steatosis. 
TABLE 6 – Semi-quantitative analysis of the histopathological changes in the liver presented by the animals in the control 
group and group 2 for a period of time.  
Time (hour)
   Control 
   Group*
  
12h
24h 48h 72h 120h P value1
N % N % N % N % N % N %
NECROSIS


























   Mild 0 0% 4 66,7% 1 16.7% 1 16.7% 1 25% 0 0%
     Moderate 0 0% 2 33.3% 2 33.3% 2 33.3% 1 25% 0 0%
  Intense 0 0% 0 0% 3 50% 3 50% 1 25% 0 0%
APOPTOSiS 5 100% 6 100% 6 100% 6 100% 4 100% 4 100% <0.001
Absent 4 80% 0 0% 0 0% 0 0% 1 25% 3 75%
Mild 1 20% 0 0% 0 0% 2 33.3% 3 75% 1 25%
  Moderate 0 0% 2 33.3% 2 33.3% 2 33.3% 0 0% 0 0%
Intense 0 0% 4 66,7% 4 66.7% 2 33.3% 0 0% 0 0%
*Material loss of one animal 
1Descriptive level of Kruskal-Wallis test
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Discussion
Acute liver failure is a severe condition and in liver 
transplants, most of the time constitutes to as the only life saving 
therapy. Several animal models for acute liver failure, using rats 
have been described and the use of d-galactosamine to induce liver 
failure is the most widely used.
D-galactosamine is an amino sugar metabolized in the 
liver via galactose, which leads to depletion of uridine nucleotides 
and blocks the liver transition, thus resulting in massive diffuse 
necrosis of the liver11. Studies using radio labeled d-galactosamine 
have established the specific hepatotoxicity of this drug: virtually 
100% of the drug is metabolized by the liver12. 
Keppler et al.13 were among the first researchers to 
use d-galactosamine to induce acute liver failure in Wistar rats. 
After injecting intraperitoneally 1.5 g/kg of d-galactosamine, 
divided into 6 doses of 0.25 g/kg, AST, ALT, prothrombin activity, 
bilirubin, prothrombin time, total proteins and Hb in sacrificed 
rats after 25.5 and 48 hours were evaluated. Similar to what was 
found in this present study, these authors reported that AST, ALT 
and bilirubin levels and prothrombin time were greater at 25.5 
hours after the d-galactosamine injection. Histologically, they 
found intense parenchymatous necrosis and intense lobular and 
periportal inflammatory infiltrate with progression of injury at 48 
hours after the injection, thus showing complex dissociation of the 
parenchyma. These data were similar to what was found in this 
present study. 
Watanabi et al.14 injected a dose of 1.3 g/kg of 
d-galactosamine intraperitoneally into three Sprague-Dawley 
rats. In addition to ALT, bilirubin and prothrombin time, these 
authors ascertained the ammonia, cholesterol and glucagon levels 
and evaluated liver and brain histology at 24 and 48 hours after 
the injection. They also produced electroencephalograms on the 
rat to identify encephalopathy findings. The EEGs showed slow 
high-amplitude waves compatible with hepatic encephalopathy, 
while histological analysis showed brain edema. Unlike this, the 
histological analysis on the brain among the rats in this present 
study was normal, although the clinical findings of numbness, 
spasms, seizures and coma were presented, also in Watanabi et 
al.14 study, compatible hepatic encephalopathy were reported.
Dixit et al.15 correlated the clinical neurological findings 
from rats subjected to intraperitoneal injection of 0.85 mg/kg of 
d-galactosamine, with enzymatic alterations and hepatic histology. 
The peak hepatic enzyme alterations coincided with the highest 
degree of histological liver failure, which occurred 48 hours after 
the injection, the rats presented second degree of encephalopathy 
(confusion and numbness). The authors also affirmed that 
d-galactosamine did not have any direct effect on the blood-
brain barrier, thus suggesting that the brain edema found in the 
histological analysis was due to a cytotoxic effect that led to the 
formation of vasogenic edema.
From the analysis on liver failure evolution over the 
course of time and laboratory alterations in this present study was 
that the peak for liver enzymes also coincided with the time of 
greater intensity of necrosis, apoptosis and hepatic bleeding was 
noted, as Dixit et al.15 had also observed. However, this peak 
occurred 24 hours after the d-galactosamine injection, i.e. earlier 
than what Dixit et al.15 had observed. One explanation for this is 
the difference between the doses used in each study, thus, it could 
be asked whether the evolution of the liver failure is dependent on 
the dose administered. 
Zhang et al.16 analyzed rats for a period longer than 48 
hours. To evaluate the use of granulocytic colony stimulating 
factor in ALF, 160 Wistar rats were analyzed and subjected to 
intraperitoneal d-galactosamine injection of 1.4 g/kg. Eighty 
rats received d-galactosamine subcutaneous, followed by saline 
solution 2 hours after the d-galactosamine injection, once a day for 
five consecutive days. For the other eighty rats, 2 hours after the 
d-galactosamine injection, granulocytic colony stimulating factor 
was administered once a day for five days. In the d-galactosamine 
+ saline group, thirty rats were observed over the period of time 
to evaluate the mortality and 50 rats were sacrificed at different 
hours after the injection (six at a time): 6, 12, 24, 72, 120 hours 
and 7 days. 
Those authors only analyzed hepatic histology and 
ALT enzyme alterations. In the group that only received 
d-galactosamine + saline, the mortality rate was found to be 66.7% 
(20/30), i.e. similar to the results in this present study, and the 
progression of histological lesions through different hours also 
corresponded to the findings in this present study. However, the 
peak of ALT and the histological injury found by those authors 
was at a later stage, occurring 72 hours after the d-galactosamine 
injection. Reversibility of liver failure was also proven by Zhang 
et al.16 showing liver histological sections with regeneration 
of hepatocytes and vacuolar degeneration five days after the 
injection, and normal ALT values seven days after the injection. 
The group that received granulocytic colony stimulating factor 
presented a lower mortality of 46.7% (14/30), lower ALT levels 
and lower liver failure16. The intervention was done empirically, 
without considering any clinical aspects.
D-galactosamine is an expensive drug, and it cannot be 
applied on large animals and for this reason rats are commonly 
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used, however unfortunately we are not able to get blood samples 
from the same rat during different periods of time, in which it 
would be ideal, because of its low blood volume. D-galactosamine 
is likely to cause irritability to the skin and eyes, it must be handled 
using personal protection equipment.  
The prognosis for acute liver failure improved significantly 
after the emergency liver transplant has been performing. The one-
year survival rate reached 77%. When evaluating the prognosis 
for fulminant hepatitis, the decision regarding the need for and 
the time to proceed a liver transplant should be made as early as 
possible17. A series of prognostic criteria have been developed 
with the aim to select candidates for a liver transplant the best way 
possible. 
The criterion developed by King’s College is the most 
commonly used. It forms the basis to register for emergency 
liver transplant in the United Kingdom and has been widely 
disseminated internationally8. 
Meta-analysis evaluated the survival among patients 
with ALF that was not induced by paracetamol showed moderate 
sensitivity (70%, 95% CI 61-79%) and higher specificity (80%, 
95% CI 73-87%), in which the capacity to discriminate between 
the need for transplant and the lack to need were evaluated by 
ROC curve, with Q of 0.7837. Another meta-analysis performed 
to evaluate King’s College criterion among patients with ALF, 
secondary to paracetamol, revealed sensitivity of 69% and 
specificity of 92%, but Q was 0.6118. To overcome these limitations, 
other alternative prognostic systems might be used6.
Clichy-Villejuif criteria are mostly used in France, and 
include hepatic encephalopathy and factor V level < 20% among 
patients under 30 years of age and < 30% among patients over 30 
years of age. Using Clichy´s criteria, a recent study conducted in 
France evaluated 808 patients who underwent an emergency liver 
transplant due to ALF between 1997 and 2010. The sensitivity, 
specificity and positive and negative predictive values for Clichy´s 
criteria were 75%, 56%, 50% and 79%, respectively, for ALF due 
to paracetamol, were 69%, 50%, 64% and 55%, respectively, for 
ALF unrelated to paracetamol17. 
Comparing this present study with other similar ones, it 
was found that this was the first study to evaluate King’s College 
and Clichy´s criteria in an animal model for ALF. It was observed 
that 12 hours after d-galactosamine injection, the mice presented a 
median INR > 6.5, thus fulfilling King’s College criterion and that, 
24 hours later, factor V reached levels lower than 30%, fulfilling 
Clichy´s criterion. This finding may indicate the best time to 
intervene in this model by testing new therapeutic approaches.
Transplantation of hepatocytes, encapsulated hepatocytes 
and stem cells may contribute as a support therapy until the liver 
has recovered from the acute event, possibly avoiding liver 
transplantation. There are advantages of having less surgical risk 
and limited duration of taking immunosuppressive medication.
Conclusion
King’s College and Clichy´s criteria were fulfilled 
12 hours after the d-galactosamine injection and this time may 
represent the best time to intervene in this acute liver failure 
animal model. 
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